Primary care diabetes, Год журнала: 2024, Номер unknown
Опубликована: Сен. 1, 2024
Язык: Английский
American Journal of Kidney Diseases, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 1, 2024
Язык: Английский
Процитировано
17
Addiction Science & Clinical Practice, Год журнала: 2025, Номер 20(1)
Опубликована: Фев. 5, 2025
Abstract Background Unhealthy alcohol use, a spectrum of use inclusive risky consumption and disorder (AUD), is leading cause preventable death in the United States. Most people with unhealthy do not receive evidence-based treatment. This four-arm factorial design randomized trial will assess whether population health management (PHM) clinical care (CCM) support for primary providers (PCPs) are associated improved AUD treatment engagement among their patients, beyond electronic record (EHR) prompting decision alone. Methods PCPs from an urban safety-net hospital-based clinic to one four groups (1) EHR best practice advisory (BPA) tools (BPA), (2) BPA plus manager support, (3) (4) all three. All have access which provide chart-based advisories order set navigation. assigned PHM quarterly panel-level feedback on metrics patients. CCM facilitation processes including medication counseling, referrals, through direct patient interactions. The outcome be percent patients engaged those new diagnosis PCP’s panel. Secondary outcomes include who initiated treatment, were prescribed medications within 90 days, numerical counts range services (outpatient encounters, specialty acute healthcare utilization) this sample. We utilization secondary using Medicaid claims; remaining assessed data. Discussion study evaluate how targeted innovation alone, compared enhancements alone or combination, impact national quality measure. Findings advance understanding supports needed improve systems general settings. Trial registration ClinicalTrials.gov identifier/registration number (NCT number): NCT05492942
Язык: Английский
Процитировано
0
Primary care diabetes, Год журнала: 2025, Номер unknown
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
American Journal of Kidney Diseases, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Kidney Medicine, Год журнала: 2025, Номер unknown, С. 100995 - 100995
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Journal of the American Society of Nephrology, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 1, 2024
Key Points Implementation gaps in guideline-concordant care for CKD are associated with poor clinical outcomes. A population health management–based, multidisciplinary approach improved exposure days to sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonists compared usual care. Angiotensin-converting enzyme inhibitor/angiotensin blocker albuminuric patients statin use was not improved, nor BP control, glycemic or albuminuria testing. Background Gaps lead The Kidney Coordinated HeAlth Management Partnership (K-CHAMP) cluster randomized trial tested the effect of a management intervention versus on progression evidence-based delivery primary setting. Methods K-CHAMP included adults aged 18–85 years eGFR<60 ml/min per 1.73 m 2 moderate-high risk who were seeing nephrologist. multifaceted nephrology e-consult, pharmacist-led medication management, patient education. In this post hoc analysis, we evaluate effectiveness processes (BP annual testing) (angiotensin-converting [ACEi]/angiotensin [ARB], intensity statin, [SGLT2i], [GLP-1RA]). Given multiplicity outcomes, Benjamini–Hochberg method used control false discovery rate. Results All 1596 (754 intervention, 842 care) enrolled (mean age 74±9 years, eGFR 37±8 , 928 [58%] female, 127 [8%] Black) analyzed. After median 17-month follow-up, arm had significantly higher year SGLT2i (56 32 days; relative benefit 1.72; 95% confidence interval [CI], 1.14 2.30) GLP-1RA (78 29 2.65; CI, 1.59 3.71) adjusted analysis. At study initiation 2019, similar proportion prescribed and/or (8% 6%, respectively; rate ratio 1.23; 0 2.99), but by 2022, prescription these medications (44% 27%, 1.63; 1.32 1.94). There no significant difference any process measures ACEi/ARB statin. Conclusions effective accelerating implementation did increase improve testing individuals Clinical Trial registry name registration number: K-CHAMP, NCT03832595.
Язык: Английский
Процитировано
2
JAMA Internal Medicine, Год журнала: 2024, Номер 184(7), С. 747 - 747
Опубликована: Апрель 15, 2024
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals Network Open Cardiology Dermatology Health Forum Neurology Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility Statement 2024 American Medical Association. All Rights Reserved Search Archive Input Term Sign In Individual inCreate an Account Access through institution Purchase Options: Buy this article Rent Subscribe the journal
Язык: Английский
Процитировано
0
American Journal of Kidney Diseases, Год журнала: 2024, Номер 84(5), С. 651 - 654
Опубликована: Июль 10, 2024
Язык: Английский
Процитировано
0
Kidney International, Год журнала: 2024, Номер 106(3), С. 366 - 368
Опубликована: Авг. 20, 2024
Язык: Английский
Процитировано
0
Primary care diabetes, Год журнала: 2024, Номер unknown
Опубликована: Сен. 1, 2024
Язык: Английский
Процитировано
0